News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
finance.yahoo.com Earnings
Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have returned -7.3%, compared to the Zacks S&P 500 composite's -2.4% change. During this period, …
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Berenburg upgrades Eli Lilly stock to Buy from Hold, citing growth prospects fueled by its weight-loss drugs. Continue Reading
This article first appeared on GuruFocus. Eli Lilly and Co. (NYSE:LLY) rose 1.27% premarket after Berenberg upgraded it to Buy from Hold and lifted its price target to $1,400 from $1,220, implying roughly 22% upside from current levels. The firm's 2026 return on research …
Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against Novo Nordisk's Wegovy pill. Reuters reports that Wegovy initially held roughly 90% of …
Investing.com -- Berenberg analyst Kerry Holford upgraded Eli Lilly to buy, raising its price target to $1,400 in a note Tuesday, representing almost 25% upside, as it backs the drugmaker to extend its lead in the fast-growing obesity market. Holford told investors that the …
Quick Read LLY beat Q2 earnings by 27% and raised full-year revenue guidance to $87B, yet the stock is a Hold as net prices fell 13% and management warned prices will keep dropping. LLY trades at 37 times trailing earnings but has lagged the …
Quick Read Lilly's Q2 revenue surged 48% to $23 billion on Mounjaro and Zepbound strength; Merck grew just 5% as KEYTRUDA nears peak penetration. Lilly's raised FY2026 guidance of $85 to $87 billion and 86% gross margin make it the stronger hold, while Merck's …
Ilana Panich-Linsman/For The Washington Post via Getty Images It's hard to miss celebrity endorsements for weight-loss drugs from people like Serena Williams, who promoted GLP-1s this summer when she returned to the pro tennis circuit. She's signed a deal with Ro, a telehealth platform …
Pivotal results from TRIUMPH-2 showed retatrutide, an investigational triple hormone receptor agonist, delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes Findings from ACHIEVE-4, the largest and longest study of Foundayo in type 2 diabetes, reaffirmed its safety profile and …
Multi-program collaboration leveraging QurCan's TERP™ polymer-lipid nanoparticle delivery platform Lilly to make a strategic investment in QurCan TORONTO, September 15, 2026--(BUSINESS WIRE)--QurCan Therapeutics ("QurCan"), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, …
Eli Lilly and Company recently presented at Morgan Stanley's Global Healthcare Conference, where executive vice president Ilya Yuffa outlined efforts to expand access to its obesity medicines, including Zepbound and Foundayo, and highlighted broader international growth initiatives. This focus on widening obesity treatment access …
In the latest close session, Eli Lilly (LLY) was up +1.99% at $1,137.86. This move outpaced the S&P 500's daily loss of 0.48%. Meanwhile, the Dow experienced a drop of 0.29%, and the technology-dominated Nasdaq saw a decrease of 0.56%. Shares of the drugmaker …
Quick Read Eli Lilly (LLY) dropped 8% last month despite 48% revenue growth, leaving Citi's $1,600 Street-high target implying 45% upside. Novo Nordisk (NVO) offers only ~10% analyst upside and Merck (MRK) just ~6%, making Lilly the clear outlier for implied returns across pharma …
During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond …
Eli Lilly and Company's LLY portfolio is overwhelmingly driven by its popular GLP-1 medicines, Mounjaro and Zepbound. However, the company's broader strategy is becoming increasingly clear — leverage the substantial cash flow generated by its cardiometabolic franchise to fund strategic acquisitions, expand its pipeline, …
INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions, including BPL-003, its lead investigational program for treatment-resistant …
Quick Read Eli Lilly (LLY) earns a BUY rating with a $1,220 price target, backed by 47% revenue growth and four straight EPS beats. Novo Nordisk (NVO) trades at a forward P/E of 14 with just 2% revenue growth, making Lilly's premium valuation at …
Viking Therapeutics (NASDAQ: VKTX) has been one of the hopefuls in a big race. The biotech company aims to launch one of the world's next big weight loss drugs. The market, on track to reach nearly $100 billion by the end of the decade, …
For Immediate Release Chicago, IL – September 10, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in …
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I'll tell you… I …
In the latest close session, Eli Lilly (LLY) was down 2.21% at $1,123.91. This change lagged the S&P 500's 0.58% loss on the day. At the same time, the Dow lost 1.18%, and the tech-heavy Nasdaq lost 0.32%. Shares of the drugmaker have depreciated …
Eli Lilly and Company LLY boasts a wide range of products across cardiometabolic health, neuroscience, oncology and immunology. Cardiometabolic Health is Lilly's largest therapeutic area by a wide margin, particularly with the success of its tirzepatide medicines, Mounjaro and Zepbound. Its cardiometabolic products accounted …
Financing co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures Proceeds will advance Moonwalk's lead obesity program into the clinic and accelerate a pipeline of adipose-selective …
Eli Lilly and Company's (NYSE:LLY) Mounjaro has already become a major growth driver in diabetes treatment, and its latest FDA approval could strengthen that position by expanding what physicians can use the drug to accomplish. The FDA approved Mounjaro to reduce the risk of …
A concept image of a woman placing a psychedelic pill in her open mouth by BLACKDAY via Shutterstock_com Obesity is becoming one of healthcare's biggest long-term challenges, and treating it is creating one of the pharmaceutical industry's biggest opportunities. For many patients, managing weight …
Eli Lilly LLY and Johnson & Johnson JNJ are two leading U.S.-based healthcare companies with strong positions across the pharmaceutical and biotech industries. Both companies have significant exposure to oncology, immunology and neuroscience. J&J's business is more diversified, with treatments targeting cardiovascular and metabolic …
Investing.com -- Eli Lilly & Co is positioned for further growth in the booming obesity-drug market, with its Zepbound and Mounjaro treatments and a pipeline of next-generation therapies offering multiple avenues for upside, J.P. Morgan said in a research note. J.P. Morgan raised its …
Currently trading at around $1,160 per share, Eli Lilly (NYSE: LLY) has one of the highest stock prices in the S&P 500. While fractional stock trading means a high absolute share price doesn't hinder performance as much as it used to, there are other …
Eli Lilly and Company (NYSE:LLY) has launched Foundayo in the United Kingdom, making Britain the first European country where the company's oral treatment for weight management and type 2 diabetes is available. The pill, known chemically as orforglipron, became available through private prescription after …
Eli Lilly (LLY) has spent the last two years as the company everyone points to when they talk about weight-loss drugs. That reputation made it the most valuable pharmaceutical company in the world. It also created a problem the company now seems eager to …
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States